Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 103-108

  Kaira, Kyoichi ^a   Tomizawa, Yoshio ^b   Yoshino, Reiko ^b   Miura, Yosuke ^b,c   Yoshii, Akihiro ^b   Iwasaki, Yasuki ^a   Koga, Yasuhiko ^a   Ono, Akihiro ^a   Hisada, Takeshi ^a   Minato, Koichi ^c   Sato, Koji ^c   Kazama, Toshifumi ^c   Ishihara, Shinichi ^d   Kohyama, Kenya ^e   Fueki, Naoto ^e   Saito, Ryusei ^b   Sunaga, Noriaki ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shibukawa Medical Center   (Japan)

^c GUNMA PREFECTURAL CANCER CENTER   (Japan)

^d National Hospital Organization   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bevacizumab; Lung cancer; Non squamous NSCLC; Response rate; S 1

Indexed keywords

BEVACIZUMAB; CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; SEROTONIN 3 ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION;

BEVACIZUMAB; LUNG CANCER; NON-SQUAMOUS NSCLC; RESPONSE RATE; S-1;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PYRIDINES; TEGAFUR; TREATMENT OUTCOME;

EID: 84884413510     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.07.008     Document Type: Article

References (26)

1. Novell S., Le Chevalier T. Chemotherapy for non-small cell lung cancer: Part 1. Early-stage disease. Oncology (Williston Park) 2003, 17:357-364.
2. NSCLC Meta-Analysis Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625.
3. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
4. Socinski M.A., Morris D.E., Masters G.A., Lilenbaum R. American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003, 123:226S-243S.
5. Soria J.C., Mauguen A., Reck M., Sandler A.B., Saijo N., Johnson D.H., et al. Systemic review and meta-analysis of randomized, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment patients with advanced non-small-cell lung cancer. Ann Oncol 2013, 24:20-30.
6. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
7. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol 2009, 27:1227-1234.
8. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21:1804-1809.
9. Niho S., Kunitoh H., Nokihara H., Horai T., Ichinose Y., Hida T., et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 2012, 76:362-367.
10. Shirasaka T., Yamamitsu S., Tsuji A., Taguchi T. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 2000, 18:315-329.
11. Kubota K., Sakai H., Yamamoto N., Kunitoh H., Nakagawa K., Takeda K., et al. A multi-institution phase I/II trial of triweeky regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:702-706.
12. Ichinose Y., Yoshimori K., Sakai H., Nakai Y., Sugiura T., Kawahara M., et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004, 10:7860-7864.
13. Katakami N., Genma A., Sakai H., Kubota K., Nishio M., Inoue A., et al. Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701). J Clin Oncol 2012, 30. [Suppl.; abstr 7515].
14. Okamoto I., Yoshioka H., Morita S., Ando M., Takeda K., Seto T., et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a West Japan Oncology Group Study. J Clin Oncol 2010, 28:5240-5246.
15. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
17. William W.N., Kies M.S., Fossella F.V., Liu D.D., Gladish G., Tse W.H., et al. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer 2010, 116:2401-2408.
18. Patel J.D., Hensing T.A., Rademaker A., Hart E.M., Blum M.G., Milton D.T., et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009, 27:3284-3289.
19. Clément-Duchêne C., Kruptiskaya Y., Ganjoo K., Lavori P., McMillan A., Kumar A., et al. A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol 2010, 5:1821-1825.
20. Kentepozidis N., Kotsakis A., Soultati A., Agelaki S., Christophylakis Ch, Agelidou M., et al. Doecetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Cancer Chemother Pharmacol 2013, 71:605-612.
21. Leon L., Vázquez S., Gracia J.M., Casal J., Lazaro M., Firvida J.L., et al. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients. Expert Opin Pharmacother 2012, 13:1389-1396.
22. Yamada Y., Yamaguchi T., Matsumoto H., Ichikawa Y., Goto A., Kato K., et al. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs 2012, 30:1690-1696.
23. Komatsu Y., Yuki S., Sogabe S., Fukushima H., Nakatsumi H., Kobayashi Y., et al. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Acta Oncol 2012, 51:867-872.
24. Shaked Y., Henke E., Roodhart J.M.L., Mancuso P., Langenberg M.H., Colleoni M., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
25. Nukatsuka M., Saito H., Nakagawa F., Tsujimoto H., Sakamoto K., Tsukioka S., et al. Combination therapy using oral S-1 and targeted agents against human tumor xenographts in nude mice. Exp Ther Med 2012, 3:755-762.
26. Wada H., Yamamoto M., Ryuge S., Nagashima Y., Hayashi N., Maki S., et al. Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2012, 69:1005-1011.